#1
JOURNAL ARTICLE
Yi Jiang, Qinghua Zou, Nian Zhang, Jingjing Chen, Xuemeng Chen, Qingxia You, Hong Wu
WHAT IS KNOWN AND OBJECTIVE: Immune disorder is a key trigger of recurrent spontaneous abortion (RSA); meanwhile, tumour necrosis factor inhibitor (TNFi) is a fundamental therapeutic for multiple immune and inflammatory diseases. Hence, this real-world study aimed to explore the efficacy and safety of TNFi combined with intravenous immunoglobin (IVIG) and heparin therapy in RSA patients. METHODS: A total of 105 RSA patients who received TNFi+IVIG+Heparin (enoxaparin) (n = 48) or IVIG+Heparin (enoxaparin) (n = 57) were retrospectively included in this two-centre cohort study...
December 13, 2022: Journal of Clinical Pharmacy and Therapeutics
#2
REVIEW
Xibin Chen, Mohammad Hassan Sohouli, Mahsa Nateghi, Ebru Melekoglu, Somaye Fatahi
OBJECTIVE: The current study aimed to comprehensively evaluate the potential effects of mulberry consumption on cardiometabolic risk factors in adults. METHODS: Relevant articles published up to January 2021 were systematically retrieved from SCOPUS, PubMed/MEDLINE, EMBASE, and Web of Science databases. We included all randomized controlled trials (RCTs) investigating the impact of mulberry consumption on various cardiometabolic risk factors. RESULTS: The quantitative meta-analysis of 12 eligible RCTs demonstrated a significant reducing effect of mulberry consumption on haemoglobin A1c (HbA1c) (weighted mean difference [WMD]: -0...
December 12, 2022: Journal of Clinical Pharmacy and Therapeutics
#3
JOURNAL ARTICLE
Chuanming Li, Fan Yu, Wanli Xu
WHAT IS KNOWN AND OBJECTIVE: Programmed cell death protein-1 (PD-1) inhibitors synergize apatinib for anti-tumour effect by regulating tumour microenvironment, vascular endothelial growth factor, hypoxia condition, immune response, etc. This study aimed to investigate the treatment efficacy and safety of camrelizumab (PD-1 inhibitor) plus apatinib as third-line or above therapy in metastatic colorectal cancer (mCRC) patients. METHODS: Totally, 64 unresectable mCRC patients receiving camrelizumab plus apatinib (N = 31) and apatinib (N = 33) were retrospectively enrolled...
December 10, 2022: Journal of Clinical Pharmacy and Therapeutics
#4
Meng Chen, Lei Zhao, Fang Yao, Xiang Dong Yang
WHAT IS KNOWN AND OBJECTIVE: Daratumumab, an anti-CD38 monoclonalantibody, is a safe and effective antibody used in the treatment of multiple myeloma (MM), which is rarely reported to cause severe pulmonary complications. CASE SUMMARY: A 58-year-old man diagnosed with MM and preexisting interstitial lung disease developed a high fever and severe dyspnea after administering Daratumumab and bortezomib-containing regimen. Chest CT showed bilaterally and diffused ground-glass opacities and consolidations...
December 7, 2022: Journal of Clinical Pharmacy and Therapeutics
#5
JOURNAL ARTICLE
Joaquin Borrás-Blasco, Esther Vicente-Escrig, Francisco José Rodríguez-Lucena, Ana García-Monsalve, Elena Arroyo-Domingo, Raul Ferrando-Piqueres, Elvira Casterá, Andrés Navarro-Ruiz
WHAT IS KNOWN AND OBJECTIVE: The study aimed to assess acceptability and patient experience of Certolizumab (CZP) self-injection with AVA® and clarify patient device preference after switching CZP from the syringe or auto-injection pen to AVA® in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients. METHOD: A multicentre open-label, cross-sectional and prospective study among four Spanish hospitals was performed...
December 5, 2022: Journal of Clinical Pharmacy and Therapeutics
#6
JOURNAL ARTICLE
Yanjiao Du, Yan Li, Zhihui Duan, Congmin Ma, Hao Wang, Ruihua Liu, Shao Li, Yajun Lian
WHAT IS KNOWN AND OBJECTIVE: Many patients with acute ischemic stroke (AIS) develop early neurological deterioration (END), leading to disabilities or death. Thus, this study aimed to investigate the efficacy and safety of intravenous tirofiban in treating patients with AIS and END who missed the thrombolysis time window. METHODS: A total of 123 AIS-END patients participated in the study between January 2021 and December 2021. Patients were randomized into the tirofiban group (n = 63) and the control group (n = 60) based on whether a tirofiban injection was administered...
December 2, 2022: Journal of Clinical Pharmacy and Therapeutics
#7
JOURNAL ARTICLE
Phuong Thi Xuan Dong, Van Thi Thuy Pham, Linh Thi Nguyen, Anh Van Le, Thao Thi Nguyen, Hoa Dinh Vu, Huong Thi Lien Nguyen, Hoa Thi Nguyen, Susan Hua, Shu Chuen Li
WHAT IS KNOWN AND OBJECTIVE: Unintentional medication discrepancies (UMDs) are common in geriatric patients during care transitions, resulting in frequent undesirable consequences. Medication reconciliation could be a useful practice to prevent or ameliorate UMD. However, this practice in Vietnamese hospitals has not been well established or standardized. This study aims to determine the effect of pharmacist-initiated educational interventions on improving medication reconciliation practice...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#8
JOURNAL ARTICLE
Mevlut Yilmaz, Mehmet Citirik, Hanife Rahmanlar, Ali Alkan, Hakki Gursoz
WHAT IS KNOWN AND OBJECTIVE: Retinal vein occlusion (RVO) is one of the most common causes of vision loss. Anti-vascular endothelial growth factor (anti-VEGF) drugs, ranibizumab and aflibercept, and corticosteroid implants are approved treatment options for RVO-related macular edema (ME) in Turkey. To the best of our knowledge, there is no data regarding the off-label use of these drugs for RVO in English literature. We aimed to evaluate the clinical and demographic characteristics of off-label drug use applications in Turkey for RVO...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#9
REVIEW
Elham Rahmani, Tricia Lemelle, Hunter Sharp, Ehsan Smarbafzadeh, Anita Kablinger
WHAT IS KNOWN AND OBJECTIVE: Traumatic brain injury (TBI) is a major cause of disability, and it has been associated with agitation and aggression. In a previous study, we reviewed the literature to identify evidence-based pharmacological agents for treatment of agitation in TBI. Based on the results of our previous study that summarizes the findings of several systematic reviews, the use of haloperidol and benzodiazepines is not supported by the available evidence while the use of amantadine, beta blockers, antiepileptics and methylphenidate is supported by the limited available evidence...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#10
RANDOMIZED CONTROLLED TRIAL
Chu-Yun Huang, Chaur-Jong Hu, Li-Kai Huang, Elizabeth H Chang
WHAT IS KNOWN AND OBJECTIVE: Low treatment persistence and adherence in patients with dementia results in a rapid loss of disease control. This pilot study evaluated the impact of pharmacist-provided caregiver counselling on treatment persistence, adherence, quality of life (QoL) in patients with dementia, as well as caregiver's knowledge of dementia, and caregiver burden. METHODS: This prospective, randomized controlled study was performed at a hospital-based pharmacist-managed clinic from December 2017 to December 2019...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#11
JOURNAL ARTICLE
Ying Hao Cao, Ping Chi, Chen Zhou, Wen Fei Lv, Zhe Fen Quan, Fu Shan Xue
WHAT IS ALREADY KNOWN AND OBJECTIVE: Sedation is routinely provided for patients undergoing gastrointestinal endoscopy. Remimazolam tosilate is a novel and short-acting sedative agent that has been used for sedation during endoscopic procedures. The optimal dose of remimazolam in gastrointestinal endoscopy for patients with liver cirrhosis has not been elucidated. BACKGROUND: To determine the effective dose of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#12
Katrina Ciraldo, Manuel Seraydarian, James Gasper, Triveni DeFries, Marlene Martin
WHAT IS KNOWN AND OBJECTIVE: Individuals with medication adherence challenges or a preference for long-acting medications may benefit from extended-release naltrexone (XR-NTX) for treatment of alcohol use disorder (AUD). Individuals on therapeutic anticoagulation were excluded from XR-NTX studies and its safety in this population has not been reported. CASE SUMMARY: We conducted structured retrospective chart review of six individuals who received XR-NTX for AUD while on therapeutic anticoagulation between November 2019 and Deccember 2020...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#13
JOURNAL ARTICLE
Xiaohong Qin, Lingti Kong, Chenchen Wu, Xiaohua Zhang, Meng Xie, Xiaofei Wu
WHAT IS KNOWN AND OBJECTIVE: To Investigate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of high-dose tigecycline in plasma and sputum of patients with hospital-acquired pneumonia (HAP), and provide a therapeutic regimen of multidrug-resistant bacteria (MDRB) infections. METHODS: Blood/sputum samples were collected at intervals after tigecycline had reached a steady-state. Tigecycline concentrations in specimens were determined by high-performance liquid chromatography (HLPC), PK parameters were evaluated by WinNonlin software using a non-compartment model...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#14
REVIEW
Yishuo Shu, Yinping Shi, Yilei Yang, Zhonghua Dong, Qiaoyan Yi, Haiyan Shi
WHAT IS KNOWN AND OBJECTIVE: Posaconazole is the second-generation triazole antifungal agent with widespread clinical application. Posaconazole exposure is influenced by various factors such as drug interactions, disease state and diet, resulting in a high interindividual variability in many patients and failure to ensure therapeutic efficacy. Therefore, it is necessary to conduct individualized therapy on posaconazole to ensure the efficacy and safety of treatment. METHODS: Articles were identified through PubMed using the keywords such as "posaconazole," "therapeutic drug monitoring" and "Population pharmacokinetics" from 1 January 2001 to 30 April 2022...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#15
JOURNAL ARTICLE
Véronique Bilodeau, Justine Huot, Catherine Perreault, Louis-Patrick Haraoui, Carole Delorme, Johanne Poudrette, Amélie Marsot, Benoît Crevier
WHAT IS KNOWN AND OBJECTIVE?: The latest published guidelines advocate for the area under the concentration-time curve to minimal inhibitory concentration (AUC0-24h /MIC) estimated with bayesian calculations. This recommended pharmacokinetic monitoring transition is not based on randomized controlled prospective data. METHODS: In this open-label feasibility RCT, patients were assigned to have their vancomycin dosing adjusted based on bayesian-guided AUC0-24h /MIC or trough levels. Primary outcomes were consent rate, number of patients recruited per month, compliance with blood sampling schedule and compliance with bayesian software recommendations...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#16
REVIEW
Ning Ding, Luqing Zhao, Lingfei Zhu, Weijia Sun, Danyan Li, Jiake Li, Jun Zhang, Shengsheng Zhang
WHAT IS KNOWN AND OBJECTIVE: The management of biological agents during pregnancy poses challenges as maternal and infant safety must be addressed. This study aims to compare the recommendations of existing guidelines on managing the use of biologics during pregnancy, lactation for patients with inflammatory bowel disease, and the influence on neonatal vaccination. METHODS: The PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang database, China Science and Technology Journal Database and China Biomedical Database were systematically searched from the inception date to 11 May 2022, to screen all relevant guidelines...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#17
RANDOMIZED CONTROLLED TRIAL
Hany Hasan Elsayed, Ihab Ali, Mohammed Abdel-Gayed, Aly Mohamad Warda, Assem Adel Moharram
WHAT IS KNOWN AND OBJECTIVE: Tietze syndrome is a rare form of chest wall costochondritis with joint swelling which can cause significant chest pain and decline in ability of daily activities. There is no standardized treatment protocol. The aim of this study was to assess the efficacy of adding oral steroids in addition to other non- steroidal treatment in improvement of pain and quality of life (QOL) in patients with Tietze syndrome. METHODS: Forty patients with Tietze syndrome were randomly divided into two treatment groups: (1) One week of prednisolone 40 mg daily followed by 1 week of prednisolone 20 mg daily followed by 1 week of 10 mg with 3 weeks of non-steroidal anti-inflammatory drug (NSAID) treatment (n = 20); (2) three weeks of NSAID treatment only (n = 20)...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#18
REVIEW
Dongxuan Li, Jinghui Gou, Jie Dong, Yuzhu Dong, Xin Xi, Cheng Chen, Qian Du, Songqing Liu
WHAT IS KNOWN AND OBJECTIVE: Diabetic ketoacidosis (DKA) may occur during asparaginase use. However, limited by the study population, the association between asparaginase and DKA has not been elucidated. The purpose of this study was to determine the potential association between asparaginase and DKA and analyse related clinical characteristics and possible risk factor. METHODS: Disproportionality analysis with the reporting odd ratio (ROR) was used to detect the adverse reaction signals of asparaginase-associated DKA in Food and Drug Administration Adverse Event Reporting System (FAERS)...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#19
RANDOMIZED CONTROLLED TRIAL
Na Yang, Bin Cao
WHAT IS KNOWN AND OBJECTIVE: The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA). METHODS: In this double-centre, randomized, controlled study, 120 CKD patients complicated with HUA were recruited and randomly assigned to low-dose febuxostat group (20 mg/day) or allopurinol group (200 mg/day) at 1:1 ratio. The serum creatinine (Scr), serum uric acid (SUA), and estimated glomerular filtration rate (eGFR) were measured at baseline (M0), month (M) 1, M3, and M6...
December 2022: Journal of Clinical Pharmacy and Therapeutics
#20
JOURNAL ARTICLE
Eyup Can Polat, Alparslan Koc, Kutay Demirkan
WHAT IS KNOWN AND OBJECTIVE: Acute kidney injury (AKI) is a disorder that is commonly seen in patients in the intensive care unit (ICU) and has a detrimental impact on the patients' clinical prognosis. Although a variety of factors contribute to the development of AKI in patients, drug-induced AKI is a common occurrence in the ICU. With the widespread availability of clinical pharmacy services, the clinical pharmacist's consultation service to the healthcare team aids in the resolution of drug-related issues and the enhancement of therapeutic outcomes...
December 2022: Journal of Clinical Pharmacy and Therapeutics
journal
journal
29511
1
2